Navigation Links
Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
Date:3/4/2016

CAMBRIDGE, Mass., March 4, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the Cowen and Company 36th Annual Health Care Conference at 2:30 p.m. ET on Tuesday, March 8, 2016 in Boston, MA.

A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website.  The replay will be available within 48 hours and will be archived for a limited time.

ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders.  Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea has a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea's drug pipeline includes novel antisense drugs designed to address a number of lipid risk factors, including LDL-Cholesterol, apoC-III, triglycerides and Lp(a).  Akcea's most advanced program, volanesorsen, is in Phase 3 development to treat patients with ultra-orphan lipid disorders that are characterized by extremely high triglycerides and apoC-III, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL).  Akcea is located in Cambridge, Massachusetts. Additional information about Akcea is available at www.akceatx.com.

ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases.  Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development.  Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy.  Ionis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Ionis is available at www.ionispharma.com.

FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Ionis Pharmaceuticals Inc. and its wholly owned subsidiary, Akcea Therapeutics, Inc.  Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2015,which is on file with the SEC.  Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc. 

Logo - http://photos.prnewswire.com/prnh/20160118/323100LOGO

Logo - http://photos.prnewswire.com/prnh/20151221/317736LOGO

 


'/>"/>
SOURCE Ionis Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Akcea Therapeutics Appoints Louis St. L. ODea as Chief Medical Officer
2. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
3. Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
4. Webcast Alert: Akcea Therapeutics Conference Call
5. Chrono Therapeutics Smoking Cessation Technology Demonstrates Significant Reduction in Nicotine Cravings
6. Tobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business Results
7. Nektar Therapeutics to Present at Cowen and Companys 36th Annual Health Care Conference in Boston, MA
8. Cryoport Supports ImmunoCellular Therapeutics 120-Site Phase III Clinical Trial With Cold Chain Logistics
9. Immune Therapeutics, Inc., Appoints Two New Board Members
10. Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer
11. Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2019)... ... June 14, 2019 , ... ... a forecasting and analytics platform that helps Life Sciences Manufacturers accurately project ... for Life Sciences business leaders: accurate, automated forecasting of rebates and discounts ...
(Date:6/13/2019)... ... June 13, 2019 , ... Alliance Cost Containment, LLC (ACC) ... the healthcare space. The $5.8M in savings is in addition to $17.6M saved over ... , With an acquisition in Q4 2019, the client increased their Fortune 500 status ...
(Date:6/13/2019)... Va. (PRWEB) , ... June 13, 2019 , ... The ... new executive director to succeed current executive director Nicholas Croce Jr., MS. The search ... of the Board of Directors, past APNA Presidents, and Council and Chapter leaders. , ...
Breaking Medicine Technology:
(Date:6/19/2019)... ... , ... Expanding its commitment to the welfare of children through its new ... for Caterina’s Club during its annual West Coast gala - Notte di Savoia ... donated for the Southern California-based charity from funds raised by the event. The grant ...
(Date:6/19/2019)... ... June 19, 2019 , ... Ovation® Fertility scientists have been invited to present ... Embryology (ESHRE) Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s oral presentation ... both the Basic Science Award for Oral Presentation and the Fertility Society of Australia ...
(Date:6/18/2019)... ... June 18, 2019 , ... Cosmetic Town, an online ... of cosmetic facial rejuvenation in June. The Cosmetic Town website will showcase cosmetic ... performing various methods of cosmetic facial rejuvenation and videos that take viewers behind ...
(Date:6/18/2019)... PLEASANTON, Calif. (PRWEB) , ... June 18, 2019 ... ... (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced ... designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Aaron ...
(Date:6/16/2019)... Calif. (PRWEB) , ... June 14, 2019 , ... ... / Cyber Security solutions, today announced it has received the coveted “2019 ... award winning DLP that Works Platform along with the latest additions to its ...
Breaking Medicine News(10 mins):